Business Context and Reporting Period
This Form 8-K was filed by Hancock Jaffe Laboratories, Inc. on September 21, 2021. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Irvine, California. The filing reports a strategic rebranding and operational pivot effective October 1, 2021.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate events rather than financial performance data.
Material Changes
- Corporate Name Change: The company will change its name from Hancock Jaffe Laboratories, Inc. to enVVeno Medical Corporation.
- Ticker Symbol Update: Trading symbols on The NASDAQ Stock Market LLC will change from HJLI and HJLIW to NVNO and NVNOW, respectively.
- Strategic Pivot: The development strategy has been updated to focus exclusively on venous disease and the advancement of the VenoValve® product.
- New Product Development: The company has initiated development of a second product for the treatment of venous disease, expected to be unveiled in mid-2022.
Guidance, Outlook, and Risks
Management commentary indicates a clear shift in business focus toward venous disease solutions. The outlook includes the anticipated unveiling of a second product in mid-2022. The filing does not explicitly detail specific risks, contingencies, or unusual items beyond the operational changes described.
Investor Verification Checklist
- Confirm the effective date of the name and ticker symbol change (October 1, 2021).
- Verify the new ticker symbols (NVNO for common stock, NVNOW for warrants) on NASDAQ.
- Review the attached press release (Exhibit 99.1) for detailed information on the VenoValve® advancement and the new product pipeline.
- Monitor future filings for financial updates related to the new strategic focus, as this 8-K contains no financial data.